Why the study?
Does premorbid use of ARBs reduce severity and improve outcomes in patients with acute ischaemic stroke?
Does premorbid use of ARBs reduce severity and improve outcomes in patients with acute ischaemic stroke?
No takes yet. Share an insight, caveat, or question.
This editorial highlights retrospective evidence suggesting that premorbid ARB use may offer neuroprotective benefits, reducing severity and improving outcomes in acute ischemic stroke.
Craig S. Anderson (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: